Pharmacopeia, Inc. (ACCL) (Prev: PCOP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP)

ACCL 4.340

+7.4%

12:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (167)	4/19/2000 12:30:00 PM
From: Jim Oravetz	Read Replies (2) of 179

Pharmacopeia (PCOP) 32 3/4 +2 5/8: Like the rest of the biotech sector, PCOP has seen its stock tumble over the past six weeks... Unlike many biotech stocks, however, PCOP is profitable - and in today's market climate that is an important distinction to make if you are looking to do some bargain hunting in the group... While Briefing.com maintains that many of the small genomics outfits that were sent skyward during the sector mania won't bounce back anytime soon, we remain very high on the sector's long-term promise... And despite the group's recent volatility, we expect major drug and biotech companies to continue pouring resources into R&D due to favorable demographics, the positive regulatory environment and improvements in technology which increase the likelihood of success... As we noted on this page a few weeks back, PCOP is one of those companies that provide the technology which helps biotech and pharmaceutical companies speed up the discovery of new drugs/therapies... PCOP offers products and services to accelerate drug discovery and chemicals development integrating three platform technologies: small molecule combinatorial chemistry, high-throughput screening, and simulations software... Basically it functions as an outsourcing firm for the biotech/drug industries... In addition to being at the right place at the right time, PCOP should begin to benefit from favorable valuations... While it isn't cheap in the most traditional sense, the company current trades at 74x and 43x projected FY00 and FY01 earnings with an estimated growth rate of 50%... Corresponding PEGs (p/e over growth) of 1.48 and 0.86 are downright low for a company exhibiting that kind of growth... Toss in solid financials and a strong management team, and Briefing.com contends that PCOP is a candidate to double in price over the next 12-months... Of course, market/sector risks remain high so investors should expect continued volatility over the near-term. Briefing.com Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next